Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Emerging Pharmacotherapeutic Approaches for the Management of Sickle Cell Disease
source: Expert Opinion on Pharmacotherapy
year: 2019
authors: Torres L, Conran N
summary/abstract:Introduction:
Sickle cell disease (SCD) is an inherited disease with lifelong morbidity, whose complications include frequent acute painful vaso-occlusive episodes (VOEs) that often require hospitalization. The only pharmacotherapy currently in regular use for SCD management is hydroxyurea (hydroxycarbamide).
Areas Covered:
We review recent advances in pharmacotherapy for SCD and summarize promising synthetic agents that are in late-stage development (phase 3) for SCD.
Expert Opinion:
Emerging SCD therapies have been developed to target specific pathophysiological mechanisms of the disease, as either preventative or abortive approaches to VOEs. Continuous-use pharmacotherapeutics in late-phase development for VOE prevention include voxelotor (GBT440), which elevates hemoglobin oxygenation, and prasugrel, a platelet activation inhibitor. However, at least in the near future, it is probable that biological molecules will play a primary role in SCD preventative therapy; in combination with hydroxyurea, crizanlizumab, an anti-P-selectin monoclonal antibody, appears to reduce VOE frequency, while L-glutamine was the first substance licensed by the FDA for use in SCD in 20 years. Synthetic drugs, however, may represent key approaches for the management of individuals upon hospitalization for VOE, a major challenge for SCD. For example, rivipansel (GMI-1070), a pan-selectin inhibitor, has shown encouraging effects on hospitalization time and opioid use.
DOI: 10.1080/14656566.2018.1548610
read more
+myBinderRelated Content
-
Longitudinal Analysis of Patient Specific Predictors for Mortality in Sickle Cell DiseaseINTRODUCTION: White Blood Cell (WBC) cou...
-
Sickle Cell Disease: Tipping the Balance of Genomic Research to Catalyse Discoveries in AfricaThe completion of the Human Genome Proje...
-
Novel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
-
James D’Olimpio, MD, FACP, FAAHJames T. D'Olimpio, MD, FACP, FAAHPM is ...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Blood Transfusions: How, Why, and When? (Part 1)https://www.youtube.com/watch?v=KRjjp0Jw...
-
Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial showsTreatment with Endari (L-glutamine) le...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.